<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00389168</url>
  </required_header>
  <id_info>
    <org_study_id>CV131-052</org_study_id>
    <nct_id>NCT00389168</nct_id>
  </id_info>
  <brief_title>Irbesartan and Atenolol in Hypertensive Heart Disease</brief_title>
  <acronym>SILVHIA</acronym>
  <official_title>Randomized, Double-blind Evaluation of the Effects of Irbesartan and Atenolol on Cardiovascular Structure and Function in Subjects With Hypertension and Left Ventricular Hypertrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Heart Lung Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The renin-angiotensin-aldosterone system has been implicated in the control of structural
      changes of the heart and the vasculature, beyond the effects on blood pressure.

      This projects examines the importance of the renin-angiotensin-aldosterone system and the
      sympathetic nervous system in the control of cardiac and vascular structure and function in
      subjects with hypertension.Patients with hypertension and left ventricular hypertrophy were
      randomized to an angiotensin receptor blocker or a beta adrenergic receptor blocker for 48
      weeks. Repeat investigations of blood pressure, structure and function of the heart and the
      vascular tree, and neurohormones were performed. Two control groups, consisting of
      normotensive subjects and of hypertensive subjects with no cardiac hypertrophy were also
      examined for comparison.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We included 115 patients with hypertension and cardiac hypertrophy, established by
      echocardiography. Extensive echocardiographic examinations, ultrasonography of the carotid
      arteries, 24h Holter registrations, 24h ambulatory blood pressure monitoring monitoring,
      neurohormones and blood samples for inflammation and hemostasis markers and endothelial
      function were done at weeks 0, 12, 24, and 48. Matched control groups (1:3, i.e. 38
      normotensive subjects and 38 hypertensive subjects with no signs of hypertensive heart
      disease were examined at one occasion. All patients obtained irbesartan or atenolol for 12
      weeks; a diuretic and a calcium antagonist was added when needed thereafter in order to
      obtained a blood pressure below 140/90 mm Hg. All analyses were performed central in a core
      laboratory.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 1995</start_date>
  <completion_date type="Actual">April 1997</completion_date>
  <primary_completion_date type="Actual">April 1997</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Left Ventricular Mass Index</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <description>Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m^2).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>Treatment period was baseline to 48 weeks</time_frame>
    <description>Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular Diastolic Function Assessed by the E/A Ratio</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of Venous Plasma Angiotensin II as a Marker of the Renin-Angiotensin-Aldosterone System</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects on Carotid Artery Wall Thickness</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Changes in common carotid artery intima-media thickness, assessed by ultrasonography.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Irbesartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Irbesartan per os titrated to 300 mg od, 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Atenolol per os titrated to 100 mg od, 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Titrated to 300 mg od, 48 weeks.</description>
    <arm_group_label>Irbesartan</arm_group_label>
    <other_name>Aprovel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Titrated to 100 mg od, 48 weeks.</description>
    <arm_group_label>Atenolol</arm_group_label>
    <other_name>Tenormin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 ys old

          -  Male or female with no child bearing potential

          -  Seated blood pressure diastolic 90-115 mm Hg

          -  Left ventricular mass above 131 g/m2 for men, above 100 g/m2 for women

          -  Informed consent

        Exclusion Criteria:

          -  Coronary artery disease, heart failure or other significant cardiac disorder

          -  Cerebrovascular accident within the past 6 months

          -  A seated systolic blood pressure above 200 mm Hg

          -  Significant renal disease, collagen or vascular disease, or gastrointestinal condition

          -  Significant allergy or intolerance to study drug

          -  Alcohol or drug abuse

          -  Uncontrolled diabetes mellitus
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Kahan, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, SE-182 88 Stockholm, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska Institutet, Daprtment of Clinical Sciences, Danderyd Hospital, Cardiovascular Research Laboratory</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <results_reference>
    <citation>Malmqvist K, Kahan T, Edner M, Held C, Hägg A, Lind L, Müller-Brunotte R, Nyström F, Ohman KP, Osbakken MD, Ostergern J. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001 Jun;19(6):1167-76.</citation>
    <PMID>11403367</PMID>
  </results_reference>
  <results_reference>
    <citation>Nyström F, Malmqvist K, Ohman KP, Kahan T. Nurse-recorded and ambulatory blood pressure predicts treatment-induced reduction of left ventricular hypertrophy equally well in hypertension: results from the Swedish irbesartan left ventricular hypertrophy investigation versus atenolol (SILVHIA) study. J Hypertens. 2002 Aug;20(8):1527-33.</citation>
    <PMID>12172314</PMID>
  </results_reference>
  <results_reference>
    <citation>Malmqvist K, Kahan T, Edner M, Bergfeldt L. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILVHIA). Am J Cardiol. 2002 Nov 15;90(10):1107-12.</citation>
    <PMID>12423712</PMID>
  </results_reference>
  <results_reference>
    <citation>Malmqvist K, Ohman KP, Lind L, Nyström F, Kahan T. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Cardiovasc Pharmacol. 2003 Dec;42(6):719-26.</citation>
    <PMID>14639093</PMID>
  </results_reference>
  <results_reference>
    <citation>Müller-Brunotte R, Kahan T, Malmqvist K, Ring M, Edner M. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). Am J Hypertens. 2006 Sep;19(9):927-36.</citation>
    <PMID>16942935</PMID>
  </results_reference>
  <results_reference>
    <citation>Mörtsell D, Malmqvist K, Held C, Kahan T. Irbesartan reduces common carotid artery intima-media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study. J Intern Med. 2007 May;261(5):472-9.</citation>
    <PMID>17444886</PMID>
  </results_reference>
  <results_reference>
    <citation>Malmqvist K, Kahan T, Edner M, Bergfeldt L. Cardiac repolarization and its relation to ventricular geometry and rate in reverse remodelling during antihypertensive therapy with irbesartan or atenolol: results from the SILVHIA study. J Hum Hypertens. 2007 Dec;21(12):956-65. Epub 2007 Jul 19.</citation>
    <PMID>17637792</PMID>
  </results_reference>
  <results_reference>
    <citation>Müller-Brunotte R, Kahan T, López B, Edner M, González A, Díez J, Malmqvist K. Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA). J Hypertens. 2007 Sep;25(9):1958-66.</citation>
    <PMID>17762662</PMID>
  </results_reference>
  <results_reference>
    <citation>Kurland L, Hallberg P, Melhus H, Liljedahl U, Hashemi N, Syvänen AC, Lind L, Kahan T. The relationship between the plasma concentration of irbesartan and the antihypertensive response is disclosed by an angiotensin II type 1 receptor polymorphism: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol (SILVHIA) Trial. Am J Hypertens. 2008 Jul;21(7):836-9. doi: 10.1038/ajh.2008.190. Epub 2008 May 8.</citation>
    <PMID>18464745</PMID>
  </results_reference>
  <results_reference>
    <citation>Liljedahl S, Kahan T, Lind L, Arnlöv J. The effects of antihypertensive treatment on the doppler-derived myocardial performance index in patients with hypertensive left ventricular hypertrophy: results from the Swedish irbesartan in left ventricular hypertrophy investigation versus atenolol (SILVHIA). Echocardiography. 2009 Aug;26(7):753-8. doi: 10.1111/j.1540-8175.2008.00886.x.</citation>
    <PMID>19486119</PMID>
  </results_reference>
  <results_reference>
    <citation>Müller-Brunotte R, Kahan T, Malmqvist K, Edner M; Swedish ibesartan left ventricular hypertrophy investigation vs atenolol (SILVHIA). Blood pressure and left ventricular geometric pattern determine diastolic function in hypertensive myocardial hypertrophy. J Hum Hypertens. 2003 Dec;17(12):841-9.</citation>
    <PMID>14704728</PMID>
  </results_reference>
  <results_reference>
    <citation>Müller-Brunotte R, Edner M, Malmqvist K, Kahan T. Irbesartan and atenolol improve diastolic function in patients with hypertensive left ventricular hypertrophy. J Hypertens. 2005 Mar;23(3):633-40.</citation>
    <PMID>15716707</PMID>
  </results_reference>
  <results_reference>
    <citation>Jekell A, Malmqvist K, Wallén NH, Mörtsell D, Kahan T. Markers of inflammation, endothelial activation, and arterial stiffness in hypertensive heart disease and the effects of treatment: results from the SILVHIA study. J Cardiovasc Pharmacol. 2013 Dec;62(6):559-66. doi: 10.1097/FJC.0000000000000017.</citation>
    <PMID>24084214</PMID>
  </results_reference>
  <results_reference>
    <citation>Kurland L, Liljedahl U, Karlsson J, Kahan T, Malmqvist K, Melhus H, Syvänen AC, Lind L. Angiotensinogen gene polymorphisms: relationship to blood pressure response to antihypertensive treatment. Results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial. Am J Hypertens. 2004 Jan;17(1):8-13.</citation>
    <PMID>14700505</PMID>
  </results_reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2006</study_first_submitted>
  <study_first_submitted_qc>October 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2006</study_first_posted>
  <results_first_submitted>August 19, 2012</results_first_submitted>
  <results_first_submitted_qc>May 3, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 5, 2015</results_first_posted>
  <last_update_submitted>May 3, 2015</last_update_submitted>
  <last_update_submitted_qc>May 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Thomas Kahan</investigator_full_name>
    <investigator_title>Professor, Principal investigator and Study Chair</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Cardiac hypertrophy</keyword>
  <keyword>Angiotensin</keyword>
  <keyword>Human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Atenolol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Multicenter Swedish study. Patients with primary hypertension and left ventricular (LV) hypertrophy.</recruitment_details>
      <pre_assignment_details>All participants received a placebo washout period during 4 weeks at the beginning of the study.
One patient of the 115 included was during the course of the study diagnosed with Mb Conn (adrenal tumor causing endocrine secondary hypertension). This patient was excluded from all analyses. Thus, there are 114 patients included in the dataset.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Irbesartan</title>
          <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of hydrochlorothiazide (HCTZ) and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
        </group>
        <group group_id="P2">
          <title>Atenolol</title>
          <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of hydrochlorothiazide (HCTZ) and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atenolol</title>
          <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
        </group>
        <group group_id="B2">
          <title>Irbesartan</title>
          <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="10"/>
                    <measurement group_id="B2" value="54" spread="8"/>
                    <measurement group_id="B3" value="54" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication.</description>
        <time_frame>Treatment period was baseline to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
          </group>
          <group group_id="O2">
            <title>Irbesartan</title>
            <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>Safety was assessed by non-directed questions, and all observed and volunteered adverse events were recorded at each study visit. Serious adverse events were defined by, and reported according to the regulations of good clinical practice (GCP). none were considered related to the study medication.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Left Ventricular Mass Index</title>
        <description>Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m^2).</description>
        <time_frame>Baseline and 48 weeks</time_frame>
        <population>Data on echocardiography is not always available at all time points and for all participants. This is reflected by the number of observations, which sometimes are less than the number of participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
          </group>
          <group group_id="O2">
            <title>Irbesartan</title>
            <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Left Ventricular Mass Index</title>
          <description>Repeated measures multivariate analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks. Data are presented as left ventricular mass in gram (g) indexed for body mass index (in m^2).</description>
          <population>Data on echocardiography is not always available at all time points and for all participants. This is reflected by the number of observations, which sometimes are less than the number of participants.</population>
          <units>g/m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-6" upper_limit="4"/>
                    <measurement group_id="O2" value="-9" lower_limit="-15" upper_limit="-6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6" lower_limit="-12" upper_limit="0"/>
                    <measurement group_id="O2" value="-14" lower_limit="-22" upper_limit="-6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14" lower_limit="-20" upper_limit="9"/>
                    <measurement group_id="O2" value="-26" lower_limit="-34" upper_limit="-18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Left Ventricular Diastolic Function Assessed by the E/A Ratio</title>
        <description>Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
          </group>
          <group group_id="O2">
            <title>Irbesartan</title>
            <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Diastolic Function Assessed by the E/A Ratio</title>
          <description>Changes in left ventricular diastolic function from baseline to week 48 will be evaluated as the difference in E/A ratio. Conventional pulsed wave Doppler echocardiography was used for recordings of mitral inflow in. The peak of early (E) and late (A) mitral flow velocities were measured, and the E/A-ratio was calculated. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Some echocardiographic recordings at some time point may be of insufficient quality or missing, and the number of observations may not always correspond to the total number of participants at all time points.</description>
          <units>ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.23"/>
                    <measurement group_id="O2" value="0.10" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" spread="0.28"/>
                    <measurement group_id="O2" value="0.04" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.24"/>
                    <measurement group_id="O2" value="0.10" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <description>Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
          </group>
          <group group_id="O2">
            <title>Irbesartan</title>
            <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>Difference in Diastolic Blood Pressure. Repeated measures multivariable analysis of variance (MANOVA) at time points 0, 12, 24, and 48 weeks</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.3" lower_limit="-18.5" upper_limit="-14.0"/>
                    <measurement group_id="O2" value="-18.8" lower_limit="-21.4" upper_limit="-16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes of Venous Plasma Angiotensin II as a Marker of the Renin-Angiotensin-Aldosterone System</title>
        <description>Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
          </group>
          <group group_id="O2">
            <title>Irbesartan</title>
            <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Changes of Venous Plasma Angiotensin II as a Marker of the Renin-Angiotensin-Aldosterone System</title>
          <description>Venous plasma concentrations of angiotensin II were measured in order to study the possible associations between the activity of the renin-angiotensin-aldosteone system and changes in left ventricular mass. Further analyses of other components of the renin-angiotensin-aldosterone system and of other hormonal system (e.g. the sympathetic nervous system) have also been performed and published. Repeated measures MANOVA at time points 0, 12, 24, and 48 weeks. Data were log-transformed to avoid skewness before statistical evaluation. However, tabular data are given as mean values with 95% confidence to improve readability.</description>
          <units>pmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Weel 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-1.4" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="3.0" lower_limit="1.2" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" lower_limit="-1.4" upper_limit="-0.1"/>
                    <measurement group_id="O2" value="3.3" lower_limit="1.8" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" lower_limit="-0.9" upper_limit="0.4"/>
                    <measurement group_id="O2" value="10.0" lower_limit="5.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effects on Carotid Artery Wall Thickness</title>
        <description>Changes in common carotid artery intima-media thickness, assessed by ultrasonography.</description>
        <time_frame>Baseline to 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
          </group>
          <group group_id="O2">
            <title>Irbesartan</title>
            <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
          </group>
        </group_list>
        <measure>
          <title>Effects on Carotid Artery Wall Thickness</title>
          <description>Changes in common carotid artery intima-media thickness, assessed by ultrasonography.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.12"/>
                    <measurement group_id="O2" value="-0.01" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The entire duration of study: that is 4-6 weeks of single-blinded placebo run-in, 48 weeks of double-blinded medication, and 4 weeks following completion of the study.</time_frame>
      <desc>Defied and reported according to study protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Irbesratan</title>
          <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
        </group>
        <group group_id="E2">
          <title>Atenolol</title>
          <description>A double blind study with parallel group treatment with irbesartan or atenolol; addition of HCTZ and felodipine when needed to achieve &lt; 140/90 mm Hg</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>inadequate blood pressure reduction</sub_title>
                <description>None of withdrawals were considered likely related to the drugs studied.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>events were not documented specifically in the records available</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="58"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Kahan, MD</name_or_title>
      <organization>Karolinska Institutet, Stockholm, Sweden</organization>
      <phone>+46 8 123 568 61</phone>
      <email>thomas.kahan@ds.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

